The price of a normal medication called ampagliflosis has been reduced. Now its price has remained about tenth compared to before. This change occurred when many companies have launched the generic versions of this drug on the market. Empagliflose was developed by the German pharmaceutical company Bohringer Ingelheim (BI) and is sold as Jardians. It is a mouth medication, which helps control blood sugar (blood sugar) of type 2 diabetic patients.
Earlier, a ball was available for so much money
Earlier, a tablet of this drug was available for around 60 rupees, but now its price was only Rs 5.5 per pill. This cup was possible when companies like humanity, Alchem and Glenmark launched its generic versions on the market. Mainkind Pharma said that his empaglifelogenic medication will now be available at a rate of 5.49 RS per tablet for 10 mg of dose and RS 9.90 per tablet for 25 mg. The vice-president and managing director of the company, Rajiv Juneja, said: “We make sure that the price of the drug is no longer an obstacle in treatment.”
Arrangements to protect against false drugs
Alchem Company launched this medication under the name of “Emponom”, which was evaluated at around 80% less than the original medication. The company said that a special security band had been installed on this package of medicines to protect against false medicines. In addition, to educate patients, information related to the management of diabetes in Hindi and English was given with photos. Apart from this, an QR code has also been given, from which additional information related to diabetes, heart disease and kidney disease can be obtained in 11 languages.
How will patients get relief?
Glenmark Pharmaceuticals, based in Mumbai, also launched a generic version of Empagliflogen as “Glampa”. In addition, he also launched drugs with his mixed diet called “Glampa-L” (ampagliflose + linagliptine) and “Glamppa-m” (Empaglogen + Metformin). Alok Malik, president of Glenmark Pharma, said: “This new GLAPAMPA category drug will give an affordable and effective treatment option to patients with type 2 diabetes, which will also improve patients with heart disease.” India is called the capital of diabetes, where in 2023, according to a study by the Indian Medical Research Council (diabetes), more than 100 million people suffered from the disease. In such a situation, reducing the price of diabetes can be an important step towards reducing the growing load of this disease.
Warning: Here, the information provided here is based solely on beliefs and information. It is important to mention here that abplive.com does not confirm any type of recognition, of information. Before implementing any information or recognition, consult the expert concerned.
Read also: Happy diabetic patients! Sugar medicine can be cheaper than 10 rupees, knowing when
Discover the health tools below
Calculate your body mass index (BMI)
